Advertisement

Interaktionen zwischen Clostridium difficile und Saccharomyces boulardii

  • H.-U. Schmidt
Conference paper

Zusammenfassung

Das klinische Management Clostridium difficile-assoziierter Diarrhöen ist nach wie vor mit Problemen behaftet. Die Modifikation der zu über 99% aus Anaerobiern bestehenden intestinalen Kolonisationsflora durch Antibiotika gilt als wesentlicher prädisponierender Faktor. Ein Absetzen der einmal begonnenen antibiotischen Therapie bzw. ein Umsetzen auf weniger begünstigende Substanzen ist aufgrund der klinischen Situation (z. B. Endokarditis) oft nicht möglich. Daneben ist ein ausgeprägter postantibiotischer Effekt zu beobachten, d.h. die physiologische Darmflora erholt sich nur langsam. Bei einzelnen Patienten traten die Durchfälle erst 6 Wochen nach Beendigung der antibiotischen Therapie auf [20].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Bartlett JG (1990) Clostridium difficile: clinical considerations. Rev Infect Dis 12, (suppl 2): 243–251CrossRefGoogle Scholar
  2. 2.
    Brugier S, Patte F (1975) Antagonisme in vitro entre l’ultra-levure et différents germes bactériens. Med Paris 45: 3–8Google Scholar
  3. 3.
    Bundesanzeiger (1994) Monographie: Trockenhefe aus Saccharomyces cerevisi HANSEN CBS 5926 (Synonym: Saccharomyces boulardii). Bundesanzeiger 71: 40491Google Scholar
  4. 4.
    Buts JP, Bernasconi P, van Craynest MP, Maldague P, de Mayer R (1986) Response of human and rat small intestinal mucosa to oral administration of Saccharomyces boulardii. Pediatr Res 20: 192–196Google Scholar
  5. 5.
    Buts JP, Bernasconi P, Vaerman JP, Dive C (1990) Stimulation of secretory IgA and secretory component of immunoglobulins in small intestine of rats treated with Saccharomyces boulardii. Dig Dis Sei 35: 251–256CrossRefGoogle Scholar
  6. 6.
    Buts JP, de Keyser N, de Raedemaeker L (1994) Saccharomyces boulardii enhances rat intestinal enzyme expression by endoluminal release of polyamines. Pediatr Res 36: 522–527Google Scholar
  7. 7.
    Corthier G, Dubos F, Ducluzeau R (1986) Prevention of Clostridium difficile induced mortality in gnotobiotic mice by Saccharomyces boulardii. Can J Microbiol 32: 894–896PubMedCrossRefGoogle Scholar
  8. 8.
    Czerucka D, Nano JL, Bernasconi P, Rampal P (1989) Résponse à la toxine cholérique de deux lignées de cellules épithéliales intestinales. Effet de Saccaromyces boulardii. Gastro¬enterol Clin Biol 13: 383–384Google Scholar
  9. 9.
    Czerucka D, Nano JL, Bernasconi P, Rampal P (1991) Response aux toxines A et B de Clostridium difficile d’une lignée de cellules épithéliales intestinales de rat: IRD 98. Effet de Saccharomyces boulardii. Gastroenterol Clin Biol 15: 22–27Google Scholar
  10. 10.
    Elmer GW, McFarland LV (1987) Suppression by Saccharomyces boulardii of toxigenic Clostridium difficile overgrowth after Vancomycin treatment in hamsters. Antimicrob Agents Chemother 31: 129–131PubMedGoogle Scholar
  11. 11.
    Elmer GW, Corthier G (1990) Modulation of Clostridium difficile induced mortality as a function of the dose and the viability of the Saccaromyces boulardii used as a preventative agent in gnotobiotic mice. Can J Microbiol 37: 315–317CrossRefGoogle Scholar
  12. 12.
    Elmer GW, Surawicz CM, McFarland LV (1996) Biotherapeutic agents. A neglected modality for the treatment and prevention of selected intestinal and vaginal infections. JAMA 275: 870–876Google Scholar
  13. 13.
    Fekety R, Shah AB (1993) Diagnosis and treatment of Clostridium difficile colitis. JAMA 269: 71–75PubMedCrossRefGoogle Scholar
  14. 14.
    Gorbach SL, Chang TW, Goldin B (1987) Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 2: 1519PubMedCrossRefGoogle Scholar
  15. 15.
    Kelly CP, Pothoulakis C, LaMont T (1994) Clostridium difficile colitis. N Engl J Med 330: 257–262PubMedCrossRefGoogle Scholar
  16. 16.
    Klein SM, Elmer GW, McFarland LV, Surawicz CM, Levy RH (1993) Recovery and elimination of the biotherapeutic agent, Saccharomyces boulardii, in healthy human volunteers. Pharm Res 10: 1615–1619Google Scholar
  17. 17.
    Krammer M, Karbach U (1993) Antidiarrheal action of the yeast Saccharomyces boulardii in the rat small and large intestine by stimulating chloride absorption. Z Gastroenterol 31 (suppl 4): 73–77Google Scholar
  18. 18.
    Loeschke K, Ruckdeschel G (1992) Durchfälle unter Antibiotika: Diagnostik und Therapie. Dt Ärztebl 89: B221–B224Google Scholar
  19. 19.
    McFarland LV, Surawicz CM, Greenberg RN, Fekety R, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL, Noorani Z, Harrington G, Rubin M, Greenwald D (1994) A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibio¬tics for Clostridium difficile disease. JAMA 272: 1913–1918CrossRefGoogle Scholar
  20. 20.
    McFarland LV, Surawicz CM, Greenberg RN, Elmer GW, Moyer KA, Melcher SA, Bowen KE, Cox JL (1995) Prevention of ß-lactam-associated diarrhea by Saccharomyces boulardii compared with placebo. Am J Gastroenterol 90: 439–448PubMedGoogle Scholar
  21. 21.
    Müller J, Remus N, Harms KH (1995) Mycoserological study of the treatment of paediatric cystic fibrosis patients with Saccharomyces boulardii (Saccaromyces cerevisiae Hansen CBS 5926). Mycoses 38: 119–123PubMedCrossRefGoogle Scholar
  22. 22.
    Pothoulakis C, Kelly CP, Joshi MA, Gao N, O’Keane CJ, Castagliuolo I, LaMont T (1993) Saccaromyces boulardii inhibits Clostridium difficile Toxin A binding and enterotoxicity in rat ileum. Gastroenterol 104: 1108–1115Google Scholar
  23. 23.
    Salyers AA, Whitt DD (1994) Pseudomembranous colitis. In: Bacterial pathogenesis. A molecular approach. ASM Press, pp 282–289Google Scholar
  24. 24.
    Seal D, Borriello SP, Barclay F, Welch A, Piper M, Bonnycastle M (1987) Treatment of relapsing Clostridium difficile diarrhea by administration of a nontoxigenic strain. Eur J Clin Microbiol 6: 51–53PubMedCrossRefGoogle Scholar
  25. 25.
    Surawicz CM, Elmer GW, Speelman P, McFarland LV, Chinn J, van Belle G (1989) Prevention of antibiotic-associated diarrhea by Saccharomyces boulardii: A prospective study. Gastroenterol 96: 981–988Google Scholar
  26. 26.
    Surawicz CM, McFarland LV, Elmer GW, Chinn I (1989) Treatment of recurrent Clostridium difficile colitis with Vancomycin and Saccharomyces boulardii. Am J Gastroenterol 84: 1285–1287PubMedGoogle Scholar
  27. 27.
    Trede M, Rask-Madsen J (1989) Bacteriotherapy for chronic relapsing Clostridium difficile diarrhea in six patients. Lancet 1: 1156–1160Google Scholar
  28. 28.
    Vidon N, Huchet B, Rambaud JC (1986) Influence de Saccaromyces boulardii sur la sécrétion jéjunale induit chez le rat par le toxin cholérique. Gastroenterol Clin Biol 10: 13–16PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • H.-U. Schmidt

There are no affiliations available

Personalised recommendations